Integrative Obesity Care and Cardiometabolic Wellness

Discover the benefits of integrative obesity and cardiometabolic care for comprehensive health improvement and obesity management.

Abstract

As a clinician practicing at the intersection of chiropractic care, advanced practice nursing, and functional medicine, I have seen how obesity and its cardiometabolic comorbidities reshape health trajectories for adults aged 40 to 60. In this educational post, I synthesize the latest findings from leading researchers and landmark trials to present a comprehensive, integrative roadmap for assessing and treating obesity-driven conditions, including insulin resistance, type 2 diabetes, hypertension, dyslipidemia, heart failure with preserved ejection fraction, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, osteoarthritis, chronic pain, depression, stress, and the complex physiology of menopause and sarcopenic obesity.

I lead Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, a multidisciplinary practice where I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, integrate chiropractic care, functional medicine, rehabilitation, and personal injury services with the medical direction of our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), who brings over 40 years of internal medicine experience. Our integrative model aligns medical oversight, precise diagnostics, functional and rehabilitative interventions, and evidence-based pharmacotherapy to reduce adiposity, improve metabolic function, preserve muscle, protect joints, and elevate quality of life.

You will find clear explanations of physiological mechanisms, stepwise protocols, clinical reasoning for each technique, in-depth case studies, and practical strategies for patients and clinicians. Throughout, I include my clinical observations from sciatica.clinic and professional updates on LinkedIn to illustrate how integrative chiropractic care supports neuromusculoskeletal function, autonomic balance, pain control, and adherence to cardiometabolic treatments. The collective research foundation includes the SELECT trial (semaglutide and cardiovascular outcomes), STEP-HFpEF (semaglutide for HFpEF), SURMOUNT-1 (tirzepatide and diabetes progression), SURMOUNT-OSA (tirzepatide and sleep apnea), STEP trials (weight reduction and osteoarthritis), the Look AHEAD trial (long-term lifestyle outcomes in diabetes), MAESTRO-NASH (resmetirom for MASH), and core guideline statements from the ADA, AACE/ACE, NAMS, ACOG, AHA/ACC, and AASM.

Our Integrative Clinic in El Paso: A Multidisciplinary Care Model Led by Medical Direction and Chiropractic Integration

I lead Injury Medical Clinic PA—also known as Mission Plaza Injury Medical Clinic—in El Paso, Texas, where our team integrates multiple disciplines to provide comprehensive, patient-centered care. At the core of our model is a collaborative partnership between my roles in chiropractic and advanced nursing practice, and the medical direction of our internal medicine physician.

• My credentials and roles

• • Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST
  • Chiropractic care: neuromusculoskeletal assessment, spinal and extremity adjustments, soft tissue therapies, movement re-education
  • Functional medicine: systems-biology diagnostics, metabolic root-cause analysis, nutritional therapeutics, stress and sleep integration
  • Rehabilitation: graded loading, movement quality, joint protection
  • Personal injury care: documentation, impairment analysis, coordinated rehabilitative pathways

• Medical direction and collaborative oversight

• • Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933)
  • Over 40 years as an internist, supervising diagnostics, pharmacotherapy, and complex case management
  • Provides medical direction typical of integrative and injury clinics and safeguards evidence-based standards and patient safety

• How our team integrates care

• • Medical oversight ensures safe, effective protocols and precision in diagnostics (labs, imaging, risk stratification)
  • Chiropractic care reduces pain, restores joint mechanics, modulates autonomic tone, and enables activity.
  • Functional medicine identifies root causes across hormonal, inflammatory, metabolic, gastrointestinal, and stress domains.
  • Rehabilitation builds capacity: strength, flexibility, balance, proprioception, and graded exposure to movement.
  • Personal injury services align recovery with metabolic and musculoskeletal health goals.
  • Continuous outcome tracking: weight, waist circumference, body composition, blood pressure, A1c, lipids, pain scales, mobility, and sleep metrics

This multidisciplinary setup allows us to treat cardiometabolic disease and biomechanical dysfunction synergistically, ensuring each intervention supports the others.

Integrative Care Philosophy: Why Treating Obesity Is Treating Cardiometabolic Disease

Our guiding principle is simple and profoundly evidence-based: treating obesity is treating its downstream cardiometabolic disorders. Excess adiposity, especially visceral fat, drives inflammation, insulin resistance, dyslipidemia, hypertension, endothelial injury, sleep apnea, musculoskeletal pain, and neurohormonal imbalance. We aim not merely to reduce weight but to reduce adipose tissue—protecting and increasing lean muscle, restoring metabolic flexibility, and improving function and quality of life.

• Our core goals

• • Reduce adiposity, especially visceral fat
  • Preserve and increase lean muscle mass and strength
  • Lower cardiometabolic risk (ASCVD, heart failure, diabetes, MASLD/MASH, OSA)
  • Improve functional capacity: walking, stairs, daily activities, sport return
  • Elevate quality of life: energy, mood, sleep, pain reduction, confidence

• Clinically meaningful weight loss thresholds (Ryan & Yockey, 2017)

• • 5–5%: quality of life improvements; early glycemic gains; mobility relief
  • 5–10%: dyslipidemia improvements, knee osteoarthritis pain reduction, sleep apnea severity reduction
  • 10–15%+: hypertension improvements, diabetes remission potential, MASLD resolution potential, significant cardiovascular risk reduction

• Why percent targets matter

• • They create achievable milestones that compound toward larger health gains
  • They provide dose-response clarity for risk reduction and motivate adherence

Deconstructing Cardiometabolic Syndrome: Diagnostic Criteria and Pathophysiology

Cardiometabolic syndrome is a cluster of metabolic abnormalities that amplify risk for type 2 diabetes, stroke, and cardiovascular events. At its core is a bidirectional loop between obesity and insulin resistance, fueled by chronic low-grade inflammation from adipose tissue cytokines and adipokines.

• Diagnostic criteria (must have 3 of 5) (Grundy et al., 2005)

• • Central obesity: waist circumference > 40 inches (men) or > 35 inches (women)
  • Triglycerides ≥ 150 mg/dL or on therapy
  • Low HDL: < 40 mg/dL (men) or < 50 mg/dL (women)
  • Blood pressure ≥ 130/85 mmHg or on antihypertensives
  • Fasting glucose ≥ 100 mg/dL or dysglycemia diagnosis

• Pathophysiology

• • Adipose inflammation: TNF-alpha, IL-6, resistin, and leptin signaling derangements (Powell-Wiley et al., 2021)
  • Insulin resistance: impaired receptor signaling in muscle, liver, and fat; compensatory hyperinsulinemia
  • Neurohormonal activation: sympathetic drive, renin-angiotensin-aldosterone system, vasoconstriction, sodium retention
  • Atherogenic dyslipidemia: elevated triglycerides, suppressed HDL, ApoB particle elevation.
  • Endothelial dysfunction: reduced nitric oxide bioavailability, vascular stiffness

• Building a clinical risk profile
  • Vital signs: standardized blood pressure measurements after rest; accurate waist circumference
  • Body composition: InBody or DEXA scan to differentiate fat mass, lean mass, water, and estimate visceral adipose tissue
  • Laboratory evaluation

• • • Fasting lipid panel: TC, LDL, HDL, triglycerides
    • Advanced lipids: ApoB particle count; Lipoprotein(a) [Lp(a)] for genetic risk
    • Glycemic markers: fasting glucose, HbA1c, fasting insulin (for insulin resistance), HOMA-IR calculation

• • Cardiovascular imaging: selective Coronary Artery Calcium (CAC) scoring
  • Psychosocial evaluation: PHQ-9, GAD-7, stress assessment, sleep quality, social support, and food relationship

Our integrative framework leverages these data to tailor interventions, calibrate pharmacotherapy, and track progress longitudinally.

Obesity and Cardiovascular Disease: Inflammation, Epicardial Fat, and Atherosclerosis

Obesity harms the cardiovascular system through mechanical burden, hemodynamic stress, inflammatory signaling, and neurohormonal activation. Of particular concern is epicardial and pericardial fat—locally pro-inflammatory tissue that shares blood supply with the coronary arteries and directly accelerates atherosclerosis.

• Mechanisms of cardiovascular injury (Powell-Wiley et al., 2021)

• • Mechanical load: increased cardiac output demands; left ventricular hypertrophy risk
  • Hemodynamic changes: diastolic dysfunction; filling pressure abnormalities
  • Inflammation: endothelial damage; plaque initiation and progression
  • Neurohormonal derangement: RAAS activation; sympathetic tone; leptin resistance

• Epicardial fat (“sick fat disease”)

• • Bathes myocardium and coronary arteries with inflammatory mediators
  • Promotes atherosclerosis, atrial fibrillation via electrical remodeling and fibrosis
  • Contributes to diastolic dysfunction and HFpEF through stiffness and local inflammation

• Landmark cardiovascular evidence: SELECT trial (Ryan, Ling, & Bray, 2022)

• • Over 17,000 patients; age > 45; BMI ≥ 27; established ASCVD; no diabetes
  • Weekly semaglutide 2.4 mg vs placebo; ~40 months follow-up
  • 20% reduction in major adverse cardiovascular events (MACE)
  • Proof that treating obesity reduces heart attack and stroke risk

This is a seminal shift confirming that effective obesity pharmacotherapy confers hard cardiovascular event reduction independent of diabetes status.

Heart Failure Prevention and Treatment: Stage A Risk Modification and HFpEF

Heart failure risk is elevated in obesity through epicardial fat effects, hypertension, and diabetes. Stage A heart failure—risk factors present without structural disease or symptoms—is common in midlife and is our window for prevention.

• Stage A heart failure strategy.
  • Target weight loss: ≥ 10–15% for vascular and hemodynamic improvements
  • Four pillars

• • • Nutrition: DASH and Mediterranean patterns emphasizing fruits, vegetables, lean protein, healthy fats, and reduced sodium
    • Physical activity: ≥ 150 minutes per week of moderate-intensity activity, plus resistance training
    • Sleep optimization: 7–8 hours nightly; screening and treatment for OSA
    • Pharmacological support: GLP-1 receptor agonists (e.g., semaglutide) to achieve meaningful weight loss; off-label application guided by risk profile

• Symptomatic HFpEF: STEP-HFpEF trial (Kosiborod et al., 2023)

• • Semaglutide improved symptoms, physical function, quality of life, and weight
  • Supports GLP-1 therapy as a primary option for HFpEF management in obesity

• Emerging evidence: tirzepatide (SUMMIT trial preliminary results)

• • Dual GIP/GLP-1 agonism shows impressive benefits for HFpEF, including reduced risk of death or worsening heart failure
  • Reinforces the metabolic-cardio synergy from incretin-based therapies

Dyslipidemia Management: ApoB, HDL, Triglycerides, and Weight-Driven Improvements

Obesity-related dyslipidemia includes high triglycerides, low HDL, and often a rise in small, dense LDL particles. Reducing adiposity transforms lipid profiles—lowering ApoB particle load and elevating HDL—particularly when combined with heart-healthy nutrition and exercise.

• Clinical approach to dyslipidemia

• • Evaluate: fasting panels, ApoB, Lp(a), ASCVD risk calculator
  • Weight reduction: 5–15% reductions dramatically improve lipid metrics (Ryan & Yockey, 2017)
  • Nutrition: low-fat Mediterranean-style diet, very high in soluble fiber (oats, barley, beans, apples, psyllium) to bind and reduce cholesterol reabsorption (Freeman et al., 2017)
  • Physical activity: ≥ 150 minutes/week moderate intensity to improve HDL and insulin sensitivity
  • Pharmacotherapy: statins remain cornerstone; anti-obesity medications synergize lipid improvements by reducing adiposity

Hypertension in Obesity: Mechanisms and Dose-Response to Weight Loss

Hypertension risk rises with age and is strongly tied to excess weight. Obesity is responsible for a significant proportion of essential hypertension—approximately 78% in men and 65% in women.

• Mechanisms (Hall et al., 2015)

• • Physical compression: visceral fat compresses kidneys; microvascular expansion is limited; peripheral resistance increases
  • Inflammation and vasoconstriction: adipose-derived cytokines inflame vessels and promote narrowing
  • Hormonal activation: RAAS upregulation leads to sodium and water retention
  • Increased cardiac output: greater force against arterial walls

• Impact of weight loss

• • Framingham data: systolic pressure increased ~ 4 mmHg per 10 lbs gained; weight loss reverses trend
  • Meta-analysis: 3–9% weight loss reduces systolic and diastolic pressures by ~ 3 mmHg
  • Clinical goal: 10–15% weight reduction for significant blood pressure effects
  • DASH diet: cornerstone nutritional strategy; potassium, magnesium, calcium support; low sodium

• Coordinated medication management

• • As blood pressure improves, deprescribing under medical direction prevents hypotension and adverse events.
  • Home monitoring enhances safety during weight-driven medication adjustments.

Insulin Resistance: Central Metabolic Dysfunction Driving Obesity, Diabetes, and Hypertension

Insulin resistance sits at the epicenter of obesity’s cardiometabolic cascade. Elevated free fatty acids, adipokine dysregulation, and chronic inflammation disrupt insulin signaling in muscle and liver, leading to hyperinsulinemia—the biochemical environment of constant storage.

• Physiologic underpinnings (Lin & Li, 2021)

• • Enlarged adipocytes leak free fatty acids, exacerbating hepatic triglyceride synthesis.
  • Hyperinsulinemia promotes lipogenesis and inhibits lipolysis
  • High insulin increases hunger (reactive hypoglycemia), cravings, and reduces metabolic rate
  • Elevated insulin drives renal sodium retention and vascular smooth muscle proliferation

• Evaluation and early identification

• • Fasting insulin with glucose; HOMA-IR calculation
  • METS-IR and related indices; mortality associations highlight risk even before diabetes diagnosis (Li et al., 2023)

• Therapeutic strategies

• • Lower-carbohydrate nutrition: reduces glycemic load, insulin demand, hepatic glucose output; shifts metabolism from storage to oxidation
  • Resistance training: increases GLUT4 translocation; enhances insulin sensitivity; preserves muscle
  • Chiropractic integration: autonomic modulation; pain reduction facilitating activity; movement quality and function
  • Pharmacotherapy: metformin (hepatic glucose production reduction); incretin-based therapies (GLP-1, dual GIP/GLP-1) for weight loss and insulin sensitivity

Understanding insulin resistance explains why “eat less, move more” often fails without hormonal recalibration; integrative strategies restore physiologic balance.

MASLD and MASH: Modern Liver Disease Nomenclature and Treatment

The shift to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) emphasizes metabolic drivers over exclusion of alcohol. Obesity and insulin resistance are central to these liver conditions.

• Prevalence and risk progression

• • Over two-thirds of MASLD patients have obesity.
  • MASH involves inflammation and hepatocyte injury; fibrosis progression increases risks for cirrhosis and hepatocellular carcinoma

• Screening and evaluation (AASLD guidance reflected across practice)

• • Liver enzymes: ALT greater than AST is a common pattern
  • Imaging: review for hepatic steatosis on prior studies
  • FIB-4 score: age, AST, ALT, platelets; stratifies risk; high-risk thresholds prompt FibroScan referral

• Treatment strategy

• • Weight reduction: ≥ 10% weight loss can resolve steatohepatitis and improve fibrosis.
  • Nutrition: Mediterranean-style, lower-carbohydrate, lower-fat pattern emphasizing whole foods
  • Physical activity: aerobic and resistance training; muscle mass improves insulin sensitivity
  • Supplementation: vitamin E in selected biopsy-proven MASH without diabetes
  • Pharmacotherapy: GLP-1 and dual GIP/GLP-1 agonists reduce liver fat via weight loss; ongoing trials
  • New FDA-approved therapy: resmetirom (Rezdiffra) for MASH with F2–F3 fibrosis (MAESTRO-NASH trial evidence)

Our approach addresses the metabolic roots—weight loss and insulin sensitivity are central levers in liver recovery.

Chronic Stress, Depression, and Obesity: Neurobiology of Eating Behavior and Adherence

Stress and depression profoundly influence obesity through neurohormonal, cognitive, and behavioral pathways. Chronic stress alters hunger and satiety, impairs executive function, and increases the brain’s reward response to palatable foods; cortisol promotes visceral adiposity and insulin resistance.

• Overlapping epidemics

• • CDC data: 43% of adults with depression are obese (Pratt & Brody, 2014)
  • Bidirectional relationship; mood disorders increase risk for obesity and vice versa

• Screening and holistic support

• • PHQ-9 for depression; GAD-7 for anxiety; PSS for stress
  • Sleep optimization: improved architecture reduces insulin resistance and cortisol
  • Nutrition and movement: whole-food patterns and gentle exercise improve mood and cognition
  • Therapy and social support: counseling for coping skills; reduce weight bias traumas
  • Pharmacotherapy: careful use with mental health providers; avoid weight-promoting agents when possible

• Weight bias in medicine

• • Patients commonly report stigma and dismissal; we create safe, empathetic environments.
  • Validating experiences and listening deeply builds trust and improves adherence.

Chiropractic care reduces pain, improves mobility, and modulates autonomic tone—loosening stress’s grip and enabling consistent engagement with health behaviors.

Musculoskeletal Pain and Mobility: Biomechanics, Inflammation, and Integrative Rehabilitation

Chronic pain and mobility loss in midlife often stem from the dual burden of mechanical overload and metabolic inflammation. Obesity multiplies joint forces and inflames cartilage through cytokines.

• Joint loading mechanics

• • Walking: knee force ~ 3x body weight
  • Stairs: ~ 6x body weight
  • Jumping: ~ 10x body weight
  • A 250-pound person experiences ~ 750 lbs across the knees while walking; ~ 1,500 lbs on stairs; ~ 2,500 lbs when jumping

• Clinical evaluation

• • Mobility, strength, balance testing
  • Timed Get-Up-and-Go test for functional capacity and fall risk
  • Pain scales; imaging as indicated

• Integrative chiropractic and physical therapy

• • Adjustments: restore joint mechanics; reduce nociception; improve spinal alignment
  • Physical therapy: strengthen musculature; improve range; teach body mechanics
  • Non-weight-bearing exercise: swimming, water aerobics, cycling to protect joints while improving cardiovascular health

• Osteoarthritis and weight loss: STEP 9 trial (Lundsgaard et al., 2023)

• • Semaglutide reduced weight and significantly lowered knee osteoarthritis pain compared to placebo
  • Supports pharmacotherapy as a pain-reduction strategy via adiposity reduction and decreased inflammatory signaling

In my clinical work, combining manual therapy, graded rehabilitation, and weight loss produces rapid improvements in mobility and pain that empower long-term adherence.

Obstructive Sleep Apnea: A “Fat Mass Disease” with Systemic Metabolic Consequences

Obstructive sleep apnea (OSA) is prevalent in obesity due to fat deposits around the upper airway, reduced muscle tone, and external compression of the chest and lungs. Repeated apneas fragment sleep, lower oxygen saturation, and drive sympathetic activation and insulin resistance.

• Screening and diagnosis

• • STOP-BANG questionnaire; Epworth Sleepiness Scale
  • Referral for polysomnography (PSG); Apnea-Hypopnea Index (AHI) staging: mild (5–15), moderate (15–30), severe (> 30)

• Treatment strategies

• • Weight reduction: 5–15% weight loss lowers AHI; mild OSA may resolve
  • CPAP compliance: mask fit, humidification, pressure titration; device usage tracking
  • Pharmacotherapy: tirzepatide FDA indication for moderate-to-severe OSA in adults with obesity (SURMOUNT-OSA trials) (Malhotra et al., 2024)

• Chiropractic considerations

• • Cervical and thoracic mobility; soft tissue techniques ease CPAP comfort
  • Breathing mechanics and rib cage mobility exercises improve respiratory function and sleep posture tolerance

Improving sleep restores metabolic regulation—leptin, ghrelin, cortisol, and insulin sensitivity—and dramatically elevates daytime energy for exercise and meal preparation.

Landmark Trials Overview: Evidence Backbone of Modern Obesity Medicine

A brief synthesis of key trials guiding our protocols:

• Cardiovascular outcomes

• • SELECT: Semaglutide reduced MACE by 20% in overweight/obesity patients with established ASCVD and no diabetes (Ryan, Ling, & Bray, 2022)

• Heart failure

• • STEP-HFpEF: Semaglutide improved symptoms, function, quality of life, and weight in HFpEF with obesity (Kosiborod et al., 2023)

• Prediabetes and diabetes progression

• • SURMOUNT-1: Tirzepatide reduced progression to type 2 diabetes by ~ 94% over three years in prediabetes and produced ~ 22.9% average weight loss (Wharton et al., 2023)

• Obesity treatment without diabetes

• • STEP 1: Semaglutide achieved ~ 14.9% average weight loss; 86.4% of prediabetes cases returned to normoglycemia (Wilding et al., 2021)

• Sleep apnea

• • SURMOUNT-OSA: Tirzepatide significantly reduced AHI in OSA with obesity; led to FDA indication (Malhotra et al., 2024)

• Osteoarthritis

• • STEP 9: Semaglutide improved weight and reduced knee osteoarthritis pain (Lundsgaard et al., 2023)

• Liver disease

• • MAESTRO-NASH: Resmetirom approved for MASH with F2–F3 fibrosis, initiating a specialized pathway for true liver pharmacotherapy

These trials show that effective obesity treatment is disease-modifying across cardiometabolic and functional domains.

Case Study: “Robert” — Integrated Management of Type 2 Diabetes, Obesity, Sleep Apnea, Hyperlipidemia, Hypertension, Knee Osteoarthritis, and Low Libido

Robert is a 55-year-old Mexican American male and data analyst with Class III obesity, type 2 diabetes, hyperlipidemia, hypertension, knee osteoarthritis, and obstructive sleep apnea with poor CPAP adherence. He reported daytime fatigue, joint pain limiting exercise, and low libido. His weight gain began in his thirties with decreasing activity due to knee pain and a sedentary job. He often skipped breakfast, ate large portions, and had intense evening sweet cravings.

• Initial medications

• • Metformin 1000 mg twice daily
  • Glipizide 10 mg daily
  • Lisinopril 20 mg daily
  • Rosuvastatin 20 mg daily

• Baseline findings

• • Weight: 275 lbs; BMI: 40.6 kg/m²
  • Waist circumference: 43 inches
  • Blood pressure: 148/92 mmHg
  • HbA1c: 8.5%; fasting glucose: 180 mg/dL
  • Lipids: triglycerides 250 mg/dL; HDL 35 mg/dL; LDL 140 mg/dL
  • Liver enzymes: AST 55 U/L, ALT 65 U/L
  • Total testosterone: 250 ng/dL
  • STOP-BANG: 6 (high risk)
  • PHQ-9: 7 (mild depression)
  • FIB-4: indeterminate
  • Stage A heart failure risk

• Integrated four-pillar plan
  • CPAP optimization: mask fit, humidification, pressure titration, device usage monitoring
  • Nutrition: low-carbohydrate, higher-protein, high-fiber whole-food pattern; eliminate ultra-processed foods
  • Physical activity: low-impact cardio (cycling, swimming), graded strengthening, joint-protective movement patterns
  • Medication management under Dr. Cardenas

• • • Discontinue glipizide to avoid hypoglycemia with incretin therapy
    • Initiate tirzepatide; continue metformin, statin, and lisinopril
    • Monitor side effects; gradual titration toward effective dose

• Sexual health approach

• • Address microvascular endothelial dysfunction with improved glycemic control and blood pressure
  • Lower inflammation via adiposity reduction; improve mood and energy through sleep optimization and movement
  • Provide mental health support; set realistic expectations

• Three-year outcomes

• • 3% total body weight reduction; waist circumference markedly improved
  • Blood pressure decreased; A1c lowered from 8.7% with early improvements within the first year
  • Triglycerides lowered; lipid profile improved
  • Knee pain reduced with weight loss; greater exercise adherence
  • Substantial quality of life improvements

My chiropractic interventions supported Robert’s adherence by reducing pain and improving movement mechanics, while medical oversight ensured safe deprescribing and titration. Robert’s case exemplifies the synergy between mechanical and metabolic care.

Sarcopenic Obesity: Hidden Epidemic Driving Frailty, Diabetes, and Functional Decline

Sarcopenic obesity combines reduced muscle mass and strength with increased fat mass, especially visceral adipose tissue. Chronic inflammation from adipose tissue catabolizes muscle, reducing resting metabolic rate and accelerating fat accumulation. Weight cycling history worsens this phenotype.

• Prevalence

• • Nearly 16% across all adults; 8% among ages 20–60; over 28% in those > 60
  • Elevated rates in prediabetes (~ 20%), type 2 diabetes (~ 35%), MASLD (~ 25%), and post-bariatric surgery (~ 22%)
  • Stark disparities: Mexican American women > 60 have reported rates as high as ~ 66.6%

• Symptoms

• • Exhaustion, weakness, “hard to move,” perceived limitation in function

• Assessment

• • Muscle function tests: grip strength, sit-to-stand
  • Body composition: BIA or DEXA for precise measurement; VAT quantification; motivational benchmarks for patients

• Treatment plan

• • Physical activity: cardiometabolic targets; resistance training ≥ 2 times/week; PT referral using sarcopenia diagnosis codes
  • Nutrition: 1.0–1.5 g/kg ideal body weight protein; space protein every 3–4 hours; emphasize animal proteins; leucine and vitamin D whey shakes
  • Inflammation reduction: whole-food patterns, micronutrient assessment
  • Pharmacotherapy: anti-obesity medications when indicated; prioritize muscle-preserving strategies

Chiropractic supports movement quality and pain reduction, enabling consistent resistance training critical for reversing sarcopenic obesity.

Case Study: “Maggie” — Perimenopausal Insulin Resistance, Prediabetes, and Abdominal Adiposity

Maggie is a 53-year-old CPA experiencing perimenopausal symptoms, gradual weight gain, and increasing abdominal adiposity. She is part of the sandwich generation and reports daily wine intake to cope with stress. Her labs and biometrics show a progressive trajectory from optimal to prediabetes over three years.

• Data trajectory (50 to 53 years)

• • Weight: 135 → 157 lbs; BMI: 23.2 → 27.5
  • Waist circumference: 33 → 36.5 inches (> 35 cutoff for women)
  • HbA1c: 5.2% → 5.8% (prediabetes)
  • Fasting glucose: 88 → 104 mg/dL
  • LDL-C: 95 → 130 mg/dL
  • Fasting insulin: increased to 11.7 μU/mL (> 7 is concerning for insulin resistance)

• Diagnoses

• • Overweight/Early Class I Obesity; abdominal adiposity
  • Prediabetes with significant insulin resistance
  • Hyperlipidemia
  • Well-controlled hypothyroidism

• Stepwise plan
  • Nutrition: lower carbohydrates; 90–100 g protein/day; high intake of vegetables and fruits; reduce nightly wine
  • Physical activity: increase intensity beyond dog-walking; begin resistance training 1–2 sessions weekly
  • Medical strategies

• • • Metformin ER: start 500 mg with evening meal; gentle titration after tolerance
    • Re-evaluate gabapentin for VMS; consider taper if ineffective or contributing to weight gain.
    • Consider menopausal hormone therapy for VMS and insulin sensitivity
    • Sleep hygiene; potential CBT-I referral
    • Anti-obesity medications if insufficient progress at 3–6 months

• Key clinical insight

• • Do not ignore progressive metabolic decline; intervene early with integrated nutrition, movement, sleep, and pharmacologic supports.

Chiropractic care prepares the musculoskeletal system for safe exercise, reducing injury risk and speeding functional gains.

Case Study: “Maria” — Post-MI, Type 2 Diabetes on Insulin, MASLD, Severe Knee Osteoarthritis, Sarcopenic Obesity

Maria is a 59-year-old health executive with a myocardial infarction history, uncontrolled type 2 diabetes, hypertension, dyslipidemia, MASLD, and severe bilateral knee osteoarthritis. She is on insulin therapy without GLP-1 therapy, and her body composition reveals extremely high fat mass and low muscle mass.

• Baseline metrics

• • BMI: 35.7 (Class II Obesity)
  • HbA1c: 7.4%
  • Triglycerides: 256 mg/dL; HDL: 37 mg/dL
  • Elevated ALT/AST consistent with MASLD
  • DEXA: body fat 57.8%; muscle mass in 4th percentile; VAT 3.4 liters; waist 43.5 inches

• Diagnoses

• • Class II Obesity with sarcopenic obesity
  • Uncontrolled type 2 diabetes
  • Hypertension; dyslipidemia, hypertriglyceridemia
  • MASLD
  • Severe knee osteoarthritis

• Integrated plan
  • Nutrition: significant carbohydrate reduction; protein elevation; anti-inflammatory whole-foods pattern
  • Physical therapy: sarcopenia and osteoarthritis program; strengthen supporting musculature; pain-mitigating modalities
  • Orthopedic referral: injections or total knee replacement candidacy assessment; advocate against bias
  • Chiropractic and rehabilitation: gentle adjustments; peripheral soft tissue therapies; adjunct modalities for pain relief; graded loading
  • Medication management

• • • Start GLP-1 receptor agonist (semaglutide): indicated for ASCVD risk reduction post-MI
    • Taper and discontinue insulin as glycemic control improves to avoid weight-promoting effects
    • Maintain statin and antihypertensives under medical oversight

• • Physical activity: non-impact cardio (swimming, water aerobics, stationary cycling); PT-guided resistance training
• Advocacy against bias

• • Older women with obesity often face dismissal or minimized options
  • Our team communicates expectations to specialists and supports the patient through decisions, ensuring equitable, evidence-based care

For Maria, aligning pharmacotherapy, PT, and chiropractic care accelerates weight loss, reduces VAT, lowers triglycerides, and restores mobility.

Menopause and Metabolic Health: Vasomotor Symptoms, Central Adiposity, Insulin Resistance, and Bone-Muscle Changes

Menopause introduces systemic shifts that elevate cardiometabolic risk: rising LDL-C, insulin resistance, central fat accumulation, muscle loss, and bone remodeling changes that predispose to osteoporosis. Vasomotor symptoms correlate with weight gain and increased waist circumference, and sleep disruption worsens metabolic dysfunction.

• Observed patterns

• • Weight gain across menopausal stages even without lifestyle change; maintenance requires adjustments.
  • Shift toward android fat distribution; reduced lean mass
  • Declines in moderate-to-vigorous activity due to pain, fatigue, stress

• Clinical priorities

• • Prevent additional weight gain
  • Reduce visceral adiposity; preserve or increase muscle; protect bone density.
  • Improve sleep, mood, and VMS; enhance functional capacity

• Strategy principle: treat obesity first

• • Lifestyle interventions: nutrition, activity, behavioral counseling, sleep and stress management
  • Pharmacotherapy: select anti-obesity medications (GLP-1 or dual GIP/GLP-1) per eligibility; avoid weight-promoting medications when viable; consider menopausal hormone therapy (NAMS, ACOG guidance)
  • Monitor cardiometabolic metrics and body composition

• Protein and anabolic resistance

• • Higher protein intake needed to overcome anabolic resistance and support muscle synthesis
  • Distribute protein across meals; combine with resistance training for maximal effect.

Chiropractic integration reduces musculoskeletal barriers, optimizes posture and movement, and may modulate autonomic balance contributing to VMS and sleep improvements.

Exercise Prescription: Low-Impact Cardiovascular Training, Resistance Sessions, and Movement Quality

Exercise is medicine for obesity, diabetes, sarcopenic obesity, and menopause-related changes. Our prescriptions emphasize safety, progression, and neuromuscular quality.

• Aerobic targets (Piercy et al., 2018)

• • 150–300 minutes per week moderate intensity or 75–150 minutes vigorous intensity
  • Spread sessions across the week; exceeding 300 minutes yields additional benefit

• Resistance training

• • At least two sessions per week
  • Focus on posterior chain strength, core stability, and upper-body compound movements.
  • Closed-chain lower extremity exercises to reduce patellofemoral stress

• Chiropractic role

• • Spinal and extremity adjustments optimize joint mechanics and motor control.
  • Myofascial techniques reduce pain and improve tissue pliability
  • Kinesiology taping and bracing for kinesthetic cues and offloading
  • Breathing mechanics training supports CPAP tolerance and exercise capacity

• Mechanistic rationale

• • Resistance work stimulates mechanotransduction in cartilage and bone; improves insulin sensitivity via GLUT4
  • Graded exposure reduces fear-avoidance and central sensitization; improves resilience and adherence.

Nutrition Therapy: Lower Carbohydrates, Higher Protein, High Fiber, Whole-Food Emphasis

We prioritize dietary strategies that reduce insulin demand, improve satiety, preserve muscle, and lower inflammation.

• Core principles

• • Lower-carbohydrate approach: mitigate postprandial hyperglycemia and hepatic glucose output
  • Higher protein: increase thermic effect; support muscle protein synthesis; counter anabolic resistance
  • High fiber: slow gastric emptying; blunt glycemic excursions; improve gut microbiota; enhance satiety
  • Whole-foods foundation: vegetables, fruits, lean proteins, healthy fats, legumes as tolerated
  • Limit ultra-processed foods: reduce emulsifiers and additives linked to hyperphagia and metabolic disruption.

• Whey protein supplementation

• • Practical tool for busy patients; leucine-enriched shakes with vitamin D to potentiate muscle synthesis

• Functional medicine integration

• • Assess micronutrient status (magnesium, vitamin D) and inflammatory markers.
  • Tailor nutrition to individual biochemistry and preferences; build sustainable patterns.

Sleep Optimization and Stress Management: Foundations of Metabolic Control

Sleep quality and stress resilience are indispensable for glycemic control, appetite regulation, and mood. We coach practical sleep hygiene and stress-downregulation methods.

• Sleep strategies (St-Onge et al., 2017)

• • CPAP adherence for OSA; mask fit adjustments; humidification; pressure optimization
  • Sleep hygiene: consistent schedules; light management; cool temperatures; minimize stimulants
  • CBT-I referral for insomnia; leverage non-pharmacological gold-standard therapy

• Stress reduction

• • Breathing exercises and biofeedback to reduce sympathetic dominance
  • Gentle mobility practices to relieve muscle tension
  • Chiropractic care reduces nociceptive stress; improves autonomic balance; supports restorative sleep

These foundations stabilize hormones (cortisol, ghrelin, leptin), restore appetite regulation, and improve energy for activity and self-care.

Pharmacotherapy Integration: Incretin-Based Therapies, Metformin, Statins, Antihypertensives, and MHT

We align pharmacotherapy with clinical goals and minimize weight-promoting effects.

• Anti-obesity medications

• • GLP-1 receptor agonists (semaglutide): significant weight loss; cardiovascular risk reduction (SELECT)
  • Dual GIP/GLP-1 receptor agonists (tirzepatide): profound weight loss; reduced diabetes progression (SURMOUNT-1); OSA indication (SURMOUNT-OSA)
  • Titration schedules and side effect monitoring; hydration and gallbladder considerations

• Diabetes management

• • Metformin ER: reduces hepatic glucose output; improves insulin sensitivity
  • Deprescribing sulfonylureas (e.g., glipizide) when starting incretins to avoid hypoglycemia
  • Careful tapering of insulin when initiating GLP-1 therapy in obesity to avoid weight promotion

• Cardiovascular risk

• • Statins: LDL lowering and ASCVD risk reduction remain foundational
  • Antihypertensives: RAAS inhibitors (e.g., lisinopril) protect kidneys and lower blood pressure; adjust dosing as weight reduces

• Menopausal hormone therapy (NAMS, ACOG)

• • Consider for VMS relief and insulin sensitivity improvements when indicated.
  • Balance risks and benefits with shared decision-making

Our medical oversight ensures safety through lab monitoring, side-effect management, and logical sequencing of agents to maximize efficacy.

Monitoring and Outcomes: Data-Driven Care Pathways

We continuously track objective metrics to demonstrate progress and guide adjustments.

• Metabolic and cardiovascular measures

• • Weight, BMI, waist circumference
  • Blood pressure; lipids (LDL, HDL, triglycerides); ApoB; Lp(a) when indicated
  • A1c; fasting glucose; fasting insulin; HOMA-IR
  • Liver enzymes; FIB-4 score; imaging for MASLD/MASH when needed
  • CAC scoring in select high-risk cases

• Functional and sleep metrics

• • Pain scales; mobility tests; Get-Up-and-Go timing
  • Exercise session logs; steps; heart rate recovery
  • CPAP usage duration and residual AHI from device reports
  • Quality of life indices and symptom checklists (including VMS)

• Behavioral tracking

• • Nutrition adherence; sleep duration; stress scores
  • Motivational interviewing and habit scaffolding to maintain momentum

Collaborative Workflow: Roles of Dr. Cardenas and Dr. Jimenez

Our clinic operates through a coordinated, patient-centered workflow ensuring safety, efficacy, and alignment across modalities.

• Dr. Cardenas

• • Internal medicine diagnostics; lab interpretation; pharmacotherapy guidance
  • Cardiometabolic risk management; deprescribing; complex case oversight

• Dr. Jimenez

• • Chiropractic neuromusculoskeletal assessments; adjustments; manual therapies
  • Rehabilitation planning; movement re-education; pain science integration
  • Functional medicine evaluation; nutrition planning; sleep and stress coaching

• Joint case reviews

• • Align priorities; refine interventions; co-manage specialist referrals
  • Support patient advocacy across disciplines and address healthcare bias

Clinical Observations from Practice: Movement Quality Enables Metabolic Success

Across sciatica.clinic and my professional updates on LinkedIn, I’ve documented how integrative chiropractic care creates the scaffold for consistent application of nutrition, sleep, and pharmacotherapy:

• Pain reduction and joint mechanics restore confidence and capacity for daily activities and structured exercise
• Autonomic modulation reduces sympathetic drive, supporting improved sleep, reduced stress, and better appetite regulation.
• Movement control training improves efficiency and reduces compensatory patterns, enhancing adherence and outcomes.
• Patients report earlier improvements in energy and mood when pain is addressed, reinforcing healthy habits.

When mobility improves, patients can prepare meals, attend therapy sessions, adhere to CPAP, and maintain exercise routines—converting clinical plans into durable health gains.

Practical Tips for Patients: Start Today, Build Momentum

• Improve CPAP use

• • Check mask fit; humidification; nightly duration; device-reported AHI

• Focus meals on protein and plants

• • Build plates around lean protein, vegetables, and high-fiber foods

• Start low-impact activity

• • Daily movement; gradually add resistance training

• Track progress

• • Sleep, exercise, meals; celebrate milestones (5%, 10%, 15% weight loss)

• Ask for help

• • Share challenges early; our team adapts plans quickly and safely

Integrative Pearls for Clinicians: Align Musculoskeletal and Metabolic Care

• Treat obesity first in menopausal care—benefits ripple across vasomotor symptoms, sleep, and mood
• Avoid weight-promoting medications where possible; transition thoughtfully to metabolic-friendly regimens
• Use objective metrics and share progress visually to reinforce patient motivation
• Collaborate across disciplines—chiropractic, internal medicine, PT, sleep medicine—to ensure safety and comprehensive care
• Address weight bias proactively—validate patient experiences and champion equitable treatment options

Conclusion: Evidence-Based Integration Transforms Midlife Health

Integrating chiropractic care, internal medicine oversight, functional medicine, rehabilitation, and targeted pharmacotherapy creates durable improvements for complex conditions in midlife—type 2 diabetes, sleep apnea, obesity, knee osteoarthritis, MASLD/MASH, hypertension, dyslipidemia, HFpEF, depression, stress, and menopausal changes. With clear goals, consistent support, and patient advocacy, we restore metabolic flexibility, reduce adiposity, preserve muscle, protect joints, and profoundly improve quality of life.

References

• Obesity and cardiovascular disease: A scientific statement from the American Heart Association (Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J. P., Gordon-Larsen, P., Lavie, C. J., … AHA Councils, 2021). Circulation, 143(21), e984–e1010.
• Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over (Ryan, D. H., & Yockey, S. R., 2017). Current Obesity Reports, 6(2), 187–194.
• Obesity: Epidemiology, pathophysiology, and therapeutics (Lin, X., & Li, H., 2021). Frontiers in Endocrinology, 12, 706978.
• Diagnosis and management of the metabolic syndrome: An AHA/NHLBI scientific statement (Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., … Spertus, J. A., 2005). Circulation, 112(17), 2735–2752.
• The SELECT trial: A landmark in obesity and cardiovascular medicine (Ryan, D. H., Ling, C. W., & Bray, G. A., 2022). Cell Metabolism, 34(12), 1819–1821.
• Semaglutide in patients with heart failure with preserved ejection fraction and obesity (Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., … STEP-HFpEF Investigators, 2023). New England Journal of Medicine, 389(12), 1069–1084.
• Obesity-induced hypertension: Role of sympathetic nervous system, leptin, and melanocortins (Hall, M. E., do Carmo, J. M., da Silva, A. A., Juncos, L. A., & Hall, J. E., 2015). Journal of the American Heart Association, 4(11), e002537.
• Trending cardiovascular nutrition controversies (Freeman, A. M., Morris, P. B., Barnard, N., Esselstyn, C. B., Ros, E., & Agatston, A., 2017). Journal of the American College of Cardiology, 69(9), 1172–1187.
• Insulin resistance and mortality in a large U.S. population (Li, X., Li, Y., Chen, Y., He, J., & Li, H., 2023). Cardiovascular Diabetology, 22(1), 253.
• Efficacy and safety of semaglutide for physical function in people with obesity and knee osteoarthritis: The STEP 9 randomized clinical trial (Lundsgaard, C., Røy, M., Darsø, L., Blædel, T., Fredberg, U., & Ellingsen, T., 2023). JAMA Network Open, 6(9), e2333504.
• Tirzepatide for the treatment of obstructive sleep apnea and obesity (Malhotra, A., Grunstein, R. R., Fietze, I., et al., SURMOUNT-OSA Study Group, 2024). New England Journal of Medicine.
• Depression and obesity in the U.S. adult household population, 2005–2010 (Pratt, L. A., & Brody, D. J., 2014). NCHS Data Brief, no 167.
• Eight-year weight losses with an intensive lifestyle intervention: The Look AHEAD study (The Look AHEAD Research Group, 2014). Obesity, 22(1), 5–13.
• Tirzepatide for the treatment of obesity with and without type 2 diabetes (Wharton, S., Blevins, T., Connery, L., et al., 2023). Diabetes, Obesity and Metabolism, 25(8), 2133–2143.
• Once-weekly semaglutide in adults with overweight or obesity (Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … Kushner, R. F., 2021). New England Journal of Medicine, 384(11), 989–1002.
• Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … Buse, J. B., 2016). New England Journal of Medicine, 375(19), 1834–1844.
• The Physical Activity Guidelines for Americans (Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., … Olson, R. D., 2018). JAMA, 320(19), 2020–2028.
• Sleep duration and quality: Impact on lifestyle behaviors and cardiometabolic health (St-Onge, M. P., Grandner, M. A., McKinnon, D., Tufik, S., & Zee, P. C., 2017). Circulation, 134(18), e367–e386.
• Regulation of muscle protein synthesis and breakdown in health and disease (Coker, R. H., & Wolfe, R. R., 2021). In Sarcopenia (pp. 35–48). Springer.
• Sarcopenia: Revised European consensus on definition and diagnosis (Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., … Zamboni, M., 2019). Age and Aging, 48(1), 16–31.
• A joint ESPEN-EASO-ESO-AGA-LASO-SEEN-SENC-SEGG consensus statement on sarcopenic obesity (Donini, L. M., Busetto, L., Bauer, J. M., Bischoff, S. C., Boirie, Y., Cederholm, T., … Barazzoni, R., 2022). Clinical Nutrition, 41(5), 1017–1029.
• ADA Standards of Medical Care in Diabetes—2024 (American Diabetes Association, 2024). Diabetes Care.
• AACE/ACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity (Garvey, W. T., Mechanick, J. I., et al., 2016). Endocrine Practice.
• AACE/ACE 2022 Obesity Clinical Practice Guidelines (AACE/ACE, 2022). Endocrine Practice.
• S. Food and Drug Administration: Tirzepatide Prescribing Information (FDA).
• NAMS 2023 Position Statement on Menopausal Hormone Therapy (North American Menopause Society, 2023). Menopause.
• ACOG Practice Bulletin: Management of Menopausal Symptoms (American College of Obstetricians and Gynecologists). Obstetrics & Gynecology.
• AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease (American Heart Association/American College of Cardiology). Circulation.
• American Academy of Sleep Medicine Position Statements (AASM). Sleep Medicine.

SEO tags: integrative chiropractic care, internal medicine oversight, El Paso injury medical clinic, Dr Alex Jimenez, Dr Maria Guadalupe Cardenas MD, obesity treatment, insulin resistance, type 2 diabetes, hypertension, dyslipidemia, cardiometabolic syndrome, epicardial fat, HFpEF, semaglutide, tirzepatide, SURMOUNT-1, SURMOUNT-OSA, SELECT trial, STEP trials, MAESTRO-NASH, MASLD, MASH, resmetirom, sleep apnea CPAP optimization, osteoarthritis pain reduction, knee OA, resistance training, low carbohydrate diet, high protein nutrition, functional medicine, personal injury care, rehabilitation, sciatica clinic, menopause weight gain, vasomotor symptoms, central adiposity, sarcopenic obesity, DEXA body composition, ApoB, Lp(a), CAC scoring, DASH diet, Mediterranean diet, stress and depression screening, PHQ-9, GAD-7, CBT-I, autonomic modulation